Literature DB >> 28780656

HUS-induced cardiac and circulatory failure is reversible using cardiopulmonary bypass as rescue.

René F Andersen1, Jesper V Bjerre2, Johan V Povlsen3, Mette Veien4, Konstantinos Kamperis2, Søren Rittig2.   

Abstract

BACKGROUND: Extra-renal involvement in hemolytic uremic syndrome (HUS) includes gastrointestinal, pancreatic, hepatic, neurological and cardiac manifestations. The current 3-5% mortality rate in HUS patients is primarily attributed to complications related to the central nervous system and the heart. In this brief report, we illustrate that severe cardiac involvement in a patient with HUS is potentially reversible using cardiopulmonary bypass as rescue. CASE-DIAGNOSIS/TREATMENT: A 12-year-old boy was diagnosed with enterohemorrhagic Escherichia coli-induced HUS related to E. coli serotypes O55:H7 and O121:H19. The patient developed anuria and hypertension of 150/105 mmHg and had neurological symptoms, with lethargy, confusion and later a tonic-clonic seizure successfully treated with midazolam. Laboratory tests on blood samples revealed acute renal failure, with a creatinine level of 3.98 mg/dL, thrombocytopenia of 47 × 109/L, lactate dehydrogenase level of 3620 IU/L, low haptoglobin (<20 mg/dL), anemia (10.0 g/dL) and schistocytes on blood smears. Peritoneal dialysis was initiated without complications. Serum potassium level was normal. At day 3, the patient suffered cardiac arrest on two separate occasions. Troponin-T, creatine kinase and creatine kinase-MB levels were significantly increased. The second episode of cardiac arrest could not be reversed with advanced cardiopulmonary resuscitation, and a cardiopulmonary bypass circuit was established. Declining cardiac pump function to a near non-contractile state with an ejection fraction of <10% was observed on echocardiography. This persisted during the following days. After the patient had been on the cardiopulmonary bypass (CPB) circuit for 7 days, the myocardium slowly recovered function. Three days later, the CPB was successfully discontinued; the echocardiography showed near-normal ejection fraction, and electrocardiography (ECG) showed sinus rhythm.
CONCLUSIONS: Fatal outcome in patients with HUS may be the result of severe cardiac involvement. The present case illustrates the need for intensive supportive care, including the use of CPB, as the cardiac symptoms in HUS patients may be reversible. We suggest the monitoring of cardiac-specific enzymes, ECG and echocardiography in high-risk patients.

Entities:  

Keywords:  Cardiac failure; Cardiopulmonary bypass; Eculizumab; HUS; Troponin

Mesh:

Year:  2017        PMID: 28780656     DOI: 10.1007/s00467-017-3736-y

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  15 in total

1.  A case series of the successful use of ECMO, continuous renal replacement therapy, and plasma exchange for thrombocytopenia-associated multiple organ failure.

Authors:  Brian C Bridges; Daphne Hardison; John Pietsch
Journal:  J Pediatr Surg       Date:  2013-05       Impact factor: 2.545

2.  Eculizumab in severe Shiga-toxin-associated HUS.

Authors:  Anne-Laure Lapeyraque; Michal Malina; Véronique Fremeaux-Bacchi; Tobias Boppel; Michael Kirschfink; Mehdi Oualha; François Proulx; Marie-José Clermont; Françoise Le Deist; Patrick Niaudet; Franz Schaefer
Journal:  N Engl J Med       Date:  2011-05-25       Impact factor: 91.245

3.  Cardiac ischemia during hemolytic uremic syndrome.

Authors:  Meena Thayu; Wayne L Chandler; Srdjan Jelacic; Carrie A Gordon; Geoffrey L Rosenthal; Phillip I Tarr
Journal:  Pediatr Nephrol       Date:  2003-02-07       Impact factor: 3.714

4.  Myocarditis and haemolytic uraemic syndrome.

Authors:  I Abu-Arafeh; E Gray; G Youngson; I Auchterlonie; G Russell
Journal:  Arch Dis Child       Date:  1995-01       Impact factor: 3.791

5.  Cardiac failure in hemolytic uremic syndrome and rescue with extracorporeal life support.

Authors:  N J Thomas; J J Messina; W J DeBruin; J A Carcillo
Journal:  Pediatr Cardiol       Date:  2005 Jan-Feb       Impact factor: 1.655

Review 6.  Direct cardiac involvement in childhood hemolytic-uremic syndrome: case report and review of the literature.

Authors:  Davide Rigamonti; Giacomo D Simonetti
Journal:  Eur J Pediatr       Date:  2016-09-23       Impact factor: 3.183

7.  Cardiac tamponade in diarrhoea-positive haemolytic uraemic syndrome.

Authors:  Javed Mohammed; Guido Filler; April Price; Ajay P Sharma
Journal:  Nephrol Dial Transplant       Date:  2008-11-25       Impact factor: 5.992

8.  Clinical course and the role of shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997-2000, in Germany and Austria: a prospective study.

Authors:  Angela Gerber; Helge Karch; Franz Allerberger; Hege M Verweyen; Lothar B Zimmerhackl
Journal:  J Infect Dis       Date:  2002-08-02       Impact factor: 5.226

9.  Eculizumab in Typical Hemolytic Uremic Syndrome (HUS) With Neurological Involvement.

Authors:  Lars Pape; Hans Hartmann; Franz Christoph Bange; Sebastian Suerbaum; Eva Bueltmann; Thurid Ahlenstiel-Grunow
Journal:  Medicine (Baltimore)       Date:  2015-06       Impact factor: 1.889

Review 10.  Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS).

Authors:  Johanna Scheiring; Sharon P Andreoli; Lothar Bernd Zimmerhackl
Journal:  Pediatr Nephrol       Date:  2008-08-13       Impact factor: 3.714

View more
  4 in total

1.  Extra-corporeal membrane oxygenation and Eculizumab: Atypical treatments for typical haemolytic uraemic syndrome.

Authors:  Matthew D Kelham; Liam Gleeson; Inma Alcalde; Rosalba Spiritoso; Alastair G Proudfoot; Marie Scully
Journal:  J Intensive Care Soc       Date:  2019-03-07

2.  Acute Myocarditis and Eculizumab Caused Severe Cholestasis in a 17-Month-Old Child Who Has Hemolytic Uremic Syndrome Associated with Shiga Toxin-Producing Escherichia coli.

Authors:  Osman Yesilbas; Can Yilmaz Yozgat; Nurver Akinci; Sirin Sonmez; Eser Tekin; Faraz Talebazadeh; Uzeyir Jafarov; Hafize Otcu Temur; Yilmaz Yozgat
Journal:  J Pediatr Intensive Care       Date:  2020-08-05

3.  Extrarenal manifestations of the hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli (STEC HUS).

Authors:  Myda Khalid; Sharon Andreoli
Journal:  Pediatr Nephrol       Date:  2018-11-01       Impact factor: 3.714

4.  Cardiac Manifestation among Children with Hemolytic Uremic Syndrome.

Authors:  Emily Sanders; Clare C Brown; Richard T Blaszak; Brendan Crawford; Parthak Prodhan
Journal:  J Pediatr       Date:  2021-04-02       Impact factor: 6.314

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.